80 million reward fund to help cancer research 2020csco public welfare bright strength report card.

(Health Times reporter Jing Chao)
The 23rd National Conference on Clinical Oncology and the 2020 China Society of Clinical Oncology (CSCO) Annual Meeting recently opened in Beijing! The two-line parallel, five-way, eight-day model creates the most timely and timely form innovation in the history of the CSCO Annual Meeting.
At a press conference on September 20, The Chairman of the Heathco Foundation of Beijing, the former Chairman of the CSCO, Professor Li Jin of The Oriental Hospital affiliated with Tongji in Shanghai, Professor Ma Jun of the Harbin Institute of Hematology and Oncology of CSCO, Vice Chairman of Shandong Cancer Hospital Yu Jinming, Vice Chairman of the Eastern War Zone General Hospital Professor Qin Shuxuan and other experts on the work of the CSCO Society during the epidemic period and the innovation highlights of this annual meeting.Jinming, Vice Chairman of Csco, Li Jin, Chairman of the Heathco Foundation of Beijing, Qin Shuxuan, Vice Chairman of csco, Ma Jun, Guo Jun attended the press conference
300 volunteers to create a standardized diagnosis and treatment of tumors
During the outbreak, the Chinese Society of Clinical Oncology (CSCO) provided practical protection to medical workers on the front line of the clinic, mobilizing a team of experts to use all available resources at special times to provide online consultation and consultation services and various publicity and education activities for the vulnerable group of cancer patients.
the "People's Famous Doctors - Top Cancer Specialists Special Series Live" public service project launched by CSCO and the Heathco foundation was launched on April 14. As of September 10, MDT answer questions 24, academic live 13, invited experts 105, live broadcast length of 5700 minutes, the network accumulated 79.4 million views, a total of more than 130 text reports, text, video, map all-media network coverage of 360 million. In addition, the Society's branches actively respond to the initiative, there are now 24 branches to mobilize more than 800 clinical cancer prevention and treatment experts, has planned more than 300 online consultation and patient education activities, will standardize the cancer diagnosis and treatment recommendations sink to the grass-roots level, to help patients on-line consultation, timely access to scientific advice on prevention and treatment.National Drug Administration Drug Review Center Of the Clinical Department of Chemical Medicines First Minister Yang Zhimin and Csco Vice Chairman Ma Jun in the CDE drug special session to conduct exchanges
tumor innovation drug research and development results debuted to show China's strength
76 articles, selected 27 oral reports, 16 wall reports, lung cancer, lymphoma, liver cancer, melanoma, cervical cancer, ovarian cancer, stomach cancer and a number of solid tumors of China's original research one by one debut, showing the scientific research strength of Chinese oncologists and international research progress.
Qin pointed out that drug innovation has always been an important cornerstone of the development of cancer treatment, encouraging the development and market of clinically innovative drugs, and calling for the optimization of the CDE drug approval process, has always been the CSCO Society's responsibility and mission.
Therefore, the conference opened a special CDE drug special session on the theme of "building technical standards to accelerate the development and listing of new anti-tumor drugs", the heads and evaluator of CDE multi-departments, analyzed and judged the current situation and challenges of China's cancer innovation drug review, interpreted the guiding principles of anti-tumor new drug technology, immunotherapy, joint development of anti-tumor drugs and other research and development reviews, will provide a higher level of interaction between clinicians, peers and pharmaceutical enterprises in the field of cancer.
80 million incentive fund to help cancer research
. Professor Li Jin, chairman of the CSCO Foundation, also said in an interview that what is most lacking in the field of oncology in China is IIT (clinical research initiated by researchers). These studies are mainly new adaptation certificate expansion studies conducted after the drug is on the market. Foreign IIT research can be supported by various institutions' public welfare funds, complementing the clinical trials initiated by the bid, and even more than the number of clinical trials initiated by the bid. More IIT is needed to help more cancer patients survive and benefit from innovative drugs and advance oncology as a whole.
CSCO Foundation's annual funding will exceed 80 million by 2020, 90% of which will go to ITT. The amount of funding for a single project can be as high as 3 to 5 million.
.